LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

LENZ Therapeutics has received approval for its aceclidine-based eye drop for presbyopia, positioning it to address a substantial 128 million-patient U.S. market. The product distinguishes itself with superior efficacy, achieving a critical sub-2mm pupil size that delivers rapid (within 30 minutes) and extended (up to 10 hours) near vision improvement, with 93% of patients reaching 20/40 or better, directly overcoming the limitations of previous market failures like VUITY. As a cash-pay product priced at $79/month, LENZ's commercial strategy emphasizes an optometry-focused sales force and a Q1 DTC campaign, with refill rates being a crucial metric for investors to gauge success and the company's ability to capture its share of the estimated $3 billion market, significantly exceeding current $350 million peak revenue forecasts.

Analysis

LENZ Therapeutics is launching its newly approved presbyopia eye drop, VIZZ (aceclidine), into a substantial 128 million-patient U.S. market, positioning it as a clinically superior alternative to AbbVie's failed entrant, VUITY. Management's strategy is built on a differentiated product profile, emphasizing rapid onset and a 10-hour duration of action, which stems from its ability to achieve a sub-2mm pupil size—a critical threshold VUITY failed to reach. Clinical data is compelling, with 93% of patients achieving functional near vision (20/40 or better) and 70% maintaining it at 10 hours. The commercial plan is a 100% cash-pay model at a validated $79 per month price point, insulated from PBM pressures. The launch strategy is a phased, two-pronged attack: first, an 88-person sales force is educating optometrists—a key lesson learned from VUITY's script data showing 80% originated from this channel. Second, a major direct-to-consumer (DTC) campaign will launch in Q1 to drive patient requests. The CEO explicitly guided investors to disregard third-party script data like IQVIA, which will not capture the significant e-pharmacy channel, and instead focus on company-reported metrics, particularly the refill rate. Management's baseline model assumes a conservative 42% refill rate, which, if achieved, would represent a significant divergence from VUITY's experience and supports a potential $3 billion market opportunity, well above the approximately $350 million in peak revenue currently implied by the company's valuation.

Key Decisions for Investors

• Investors should prioritize monitoring company-provided refill rates over initial weekly prescription data from sources like IQVIA, as sustained patient adherence is the core differentiating factor in the investment thesis versus the failed VUITY launch.
• Evaluate the effectiveness of the Q1 direct-to-consumer (DTC) campaign as a key catalyst for accelerating script growth beyond the initial physician-led adoption phase and activating a broader, previously untapped patient population.
• Benchmark the initial launch trajectory against VUITY's early script velocity (3,000-6,000 new scripts/week), but model long-term revenue based on management's guidance of a ~42% refill rate, which is the primary driver for a valuation re-rating.
• Consider establishing or adding to a long position based on the significant valuation gap between the market's implied ~$350M peak sales and management's projected multi-billion dollar opportunity, contingent on successful execution of the commercial strategy and validation of patient retention.